Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN106 (Omoprubart) in Complement-Inhibitor Naïve PNH
NCT05539248Phase 2Recruiting
- Sponsor
- Care Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omoprubart in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Care Pharmaceuticals. Started Mar 2022; status: recruiting.
02
Drugs
omoprubart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05539248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539248.